Objective To observe the effect of Fuyuan Xingnao Decoction combined with edaravone for patients with type 2 diabetes mellitus (T2DM) and cerebral infarction. Methods Ninety-eight patients with T2DM and cerebral infarction treated at Shaanxi Provincial Hospital of Traditional Chinese Medicine from May 2023 to May 2024 were selected for the randomized controlled trial, and were divided into a control group and a study group by the random number table method, with 49 cases in each group. There were 29 males and 20 females in the control group; they were (56.92±9.36) years old; the course of diabetes was (12.39 ± 3.05) years; the course of cerebral infarction was (15.82±4.01) h. There were 27 males and 22 females in the study group; they were (57.88±10.07) years old; the course of diabetes was (13.12 ± 3.03) years; the course of cerebral infarction was (16.98±4.13) h. The control group took conventional treatment and edaravone, while the study group took conventional treatment, edaravone, and Fuyuan Xingnao Decoction, for 2 weeks. The neurological function, daily living ability, glucose metabolism indicators, inflammatory factors, hemorheological indicators, and endothelial function indicators before and after the treatment, clinical efficacies, and medication safety were compared between the two groups. The statistical analysis on the data was performed using t test and χ2 test. Results After the treatment, the score of National Institutes of Health Stroke Scale (NIHSS), fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPBG), glycated hemoglobin (HbA1c), fasting insulin (FINS), homeostasis model assessment-insulin resistance index (HOMA-IR), interleukin-6 (IL-6), soluble intercellular adhesion molecule-1 (sICAM-1), tumor necrosis factor-α (TNF-α), high sensitivity C-reactive protein (hs-CRP), plasma viscosity, whole blood high shear viscosity, whole blood low shear viscosity, hematocrit, endothelin-1 (ET-1), and homocysteine (Hcy) were lower than those before the treatment in both groups (all P<0.05), and the above indicators in the study group were lower than those in the control group [6.14±2.28 vs. 10.39±3.16, (6.52±0.93) mmol/L vs. (7.18±1.06) mmol/L, (9.41±1.56) mmol/L vs. (10.35±1.62) mmol/L, (6.24±0.86)% vs. (6.85±0.92)%, (10.31±3.02) mU/L vs. (11.64±3.05) mU/L, 2.99±0.62 vs. 3.71±0.75, (6.68±2.13) ng/L vs. (9.31±2.36) ng/L, (250.89±31.65) ng/mL vs. (274.16±30.87) ng/mL, (5.07±1.43) ng/L vs. (7.12±2.24) ng/L, (7.25±2.19) mg/L vs. (9.82±2.76) mg/L, (1.57±0.16) mPa·s vs. (2.16±0.13) mPa·s, (4.27±0.41) mPa·s vs. (5.52±0.49) mPa·s, (8.09±2.07) mPa · s vs. (9.96±2.12) mPa·s, (37.85±2.47)% vs. (41.94±3.52)%, (50.86±7.18) ng/L vs. (63.49±9.22) ng/L, and (12.53±1.08) μmol/L vs. (16.94±1.27) μmol/L] (t=7.635, 3.276, 2.926, 3.391, 2.169, 5.179, 5.791, 3.684, 5.400, 5.106, 20.033, 13.695, 4.418, 6.658, 7.566, and 18.517; all P<0.05). After the treatment, the Barthel index (BI) score and nitric oxide (NO) level were higher than those before the treatment in both groups (all P<0.05), and the above indicators in the study group were higher than those in the control group [79.45±5.76 vs. 70.10±5.93 and (9.16±1.13) μmol/L vs. (7.91±1.05) μmol/L] (t=7.917 and 5.672; both P<0.05). The total clinical effective rate of the study group was higher than that of the control group [95.92% (47/49) vs. 81.63% (40/49); χ2=5.018; P<0.05]. There was no statistical difference in the total incidence rate of adverse reactions between the two groups (P>0.05). Conclusion Fuyuan Xingnao Decoction combined with edaravone for patients with T2DM and cerebral infarction can significantly regulate their glucose metabolism, reduce the levels of inflammatory factors, improve their hemorheology, neurological function, and daily living ability, and protect their vascular endothelial function.